Tags : CALAVI Study

AstraZeneca Reports Results of Calquence (acalabrutinib) in CALAVI Study for

Tuba Khan June 8, 2020

Shots: The CALAVI program involves assessing of Calquence + BSC vs BSC as monothx. in patients hospitalized with respiratory complications of COVID-19, but not on assisted ventilation. The studies are […]readmore

COVID-19 Pharma

AstraZeneca Initiates CALAVI Study Evaluating Calquence (acalabrutinib) Against COVID-19

Tuba Khan April 15, 2020

Shots: The CALAVI study is a two-part trial assessing the efficacy and safety of Calquence + BSC vs BSC as monothx. in patients hospitalized with respiratory complications of COVID-19 Part […]readmore

Tags : CALAVI Study

AstraZeneca Reports Results of Calquence (acalabrutinib) in CALAVI Study for

AstraZeneca Initiates CALAVI Study Evaluating Calquence (acalabrutinib) Against COVID-19

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : CALAVI Study

AstraZeneca Reports Results of Calquence (acalabrutinib) in CALAVI Study for

AstraZeneca Initiates CALAVI Study Evaluating Calquence (acalabrutinib) Against COVID-19

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company